VistaGen Therapeutics, Inc. (VSTA) Joins the Cardiac Research Safety Consortium
Today, VistaGen Therapeutics announced its membership in the Cardiac Research Safety Consortium, a public-private partnership launched in 2006 through an FDA Critical Path Initiative Memorandum of Understanding with Duke University. The consortium aims to support research efforts that evaluate the cardiac safety of medical products, drawing upon input from stakeholders from across industrial, academic, and governmental sectors for data sharing and expertise. VistaGen Therapeutics is the creator of CardioSafe 3D™, a novel in vitro bioassay system capable of predicting the cardiac effects, both toxic and non-toxic, of small molecule drug candidates with greater speed and precision than alternative, often-used safety…